Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 3, 2026, 9:45 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 361 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Alternative Treatment Clear all
Withdrawn No phase listed Observational

Treatment of Interstitial Cystitis/Painful Bladder Syndrome Using Alternative Techniques: Exercise, Meditation, Tai Chi

NCT00661050
View directory record Official record
Conditions
Cystitis, Interstitial
Interventions
Alternative Medicine, Tai Chi instruction and class participation or walking exercise and sitting meditation
Procedure
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Apr 11, 2024 · Synced Sep 3, 2026, 9:45 AM EDT
Completed Phase 2 Interventional

Mind-Body Therapy for Pain in Ehlers-Danlos Syndrome

NCT00001966
View directory record Official record
Conditions
Ehlers-Danlos Syndrome, Pain
Interventions
Mind-body therapy
Drug
Lead sponsor
National Human Genome Research Institute (NHGRI)
NIH
Eligibility
Not listed
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2001
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 3, 2008 · Synced Sep 3, 2026, 9:45 AM EDT
Not listed Phase 1Phase 2 Interventional Results available

Combination Chemotherapy, Rituximab, and Ixazomib Citrate in Treating Patients With Non-Hodgkin Lymphoma

NCT02481310
View directory record Official record
Conditions
Adult Burkitt Lymphoma, B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and Burkitt Lymphoma, Diffuse Large B-Cell Lymphoma, MYC Gene Mutation, Plasmablastic Lymphoma
Interventions
Cyclophosphamide, Cytarabine, Doxorubicin Hydrochloride, Etoposide, Ixazomib Citrate, Laboratory Biomarker Analysis, Methotrexate, Prednisone, Rituximab, Therapeutic Hydrocortisone, Vincristine Sulfate
Drug · Other · Biological
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2024
U.S. locations
5
States / cities
Chicago, Illinois • Medford, Massachusetts • New Brunswick, New Jersey + 2 more
Source: ClinicalTrials.gov public record
Updated Feb 20, 2022 · Synced Sep 3, 2026, 9:45 AM EDT
Not yet recruiting Phase 3 Interventional

Alternate Pre-med in Anti-Cluster of Differentiation 20 (CD20) Pilot Project

NCT07472413
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Cetirizine, Diphenhydramine
Drug
Lead sponsor
University of Miami
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Boca Raton, Florida
Source: ClinicalTrials.gov public record
Updated Jul 12, 2026 · Synced Sep 3, 2026, 9:45 AM EDT
Recruiting Phase 3 Interventional

Study of Opevesostat (MK-5684) Versus Alternative NHA in mCRPC (MK-5684-003)

NCT06136624
View directory record Official record
Conditions
Prostate Cancer Metastatic
Interventions
Opevesostat, Abiraterone acetate, Enzalutamide, Hydrocortisone, Fludrocortisone acetate, Prednisone, Dexamethasone
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
1,310 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2030
U.S. locations
48
States / cities
Orange, California • Palo Alto, California • Riverside, California + 41 more
Source: ClinicalTrials.gov public record
Updated Sep 2, 2026 · Synced Sep 3, 2026, 9:45 AM EDT
Completed Phase 3 Interventional

A Randomized, Open-Label Study of Alternative Treatment Combinations of Dideoxycytidine (HIVID; ddC) and Zidovudine (AZT) in Patients With HIV Infection

NCT00002117
View directory record Official record
Conditions
HIV Infections
Interventions
Zidovudine, Zalcitabine
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
528 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
24
States / cities
Harbor City, California • Los Angeles, California • San Diego, California + 19 more
Source: ClinicalTrials.gov public record
Updated Jun 23, 2005 · Synced Sep 3, 2026, 9:45 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

CoolSculpting of the Flank With Alternate Treatment Parameters

NCT02081196
View directory record Official record
Conditions
Body Fat Disorder
Interventions
The Zeltiq CoolSculpting System
Device
Lead sponsor
Zeltiq Aesthetics
Industry
Eligibility
18 Years to 65 Years
Enrollment
45 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
2
States / cities
Sacramento, California • Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Feb 28, 2021 · Synced Sep 3, 2026, 9:45 AM EDT
Completed Phase 1 Interventional

Safety Study of Chinese Herbal Therapy to Treat Asthma

NCT00601263
View directory record Official record
Conditions
Asthma
Interventions
Anti-Asthma Herbal Medical Intervention (ASHMI)
Drug
Lead sponsor
Xiu-Min Li
Other
Eligibility
18 Years to 55 Years
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 22, 2018 · Synced Sep 3, 2026, 9:45 AM EDT
Active, not recruiting Phase 2 Interventional

Panitumumab With or Without Trametinib in Treating Patients With Stage IV Colorectal Cancer

NCT03087071
View directory record Official record
Conditions
EGFR NP_005219.2:p.S492R, KRAS Gene Mutation, MAP2K1 Gene Mutation, Metastatic Colorectal Adenocarcinoma, Refractory Colorectal Adenocarcinoma, Stage IV Colorectal Cancer AJCC v7, Stage IVA Colorectal Cancer AJCC v7, Stage IVB Colorectal Cancer AJCC v7
Interventions
Laboratory Biomarker Analysis, Panitumumab, Trametinib
Other · Biological · Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 15, 2026 · Synced Sep 3, 2026, 9:45 AM EDT
Completed Phase 2 Interventional

Guided Imagery Response in Total Knee Replacement

NCT01491750
View directory record Official record
Conditions
Osteoarthritis
Interventions
GUIDED IMAGERY, PLACEBO
Behavioral
Lead sponsor
Kent State University
Other
Eligibility
18 Years and older
Enrollment
82 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
Akron, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 5, 2014 · Synced Sep 3, 2026, 9:45 AM EDT
Terminated Not applicable Interventional

Relaxation and Visualization Therapy for Breast Cancer Patients

NCT00691119
View directory record Official record
Conditions
Breast Cancer
Interventions
Relaxation and Visualization Therapy, Health education
Behavioral · Other
Lead sponsor
National University of Natural Medicine
Other
Eligibility
45 Years to 70 Years · Female only
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated May 9, 2013 · Synced Sep 3, 2026, 9:45 AM EDT
Completed Not applicable Interventional

Testing an Alternative Therapy for Bulimia Nervosa

NCT00773617
View directory record Official record
Conditions
Eating Disorders
Interventions
ICAT, CBT
Behavioral
Lead sponsor
Neuropsychiatric Research Institute, Fargo, North Dakota
Other
Eligibility
18 Years to 65 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
2
States / cities
Minneapolis, Minnesota • Fargo, North Dakota
Source: ClinicalTrials.gov public record
Updated Mar 28, 2018 · Synced Sep 3, 2026, 9:45 AM EDT
Terminated Phase 4 Interventional Results available

Buprenorphine Treatment: A Safe Alternative for Opioid Dependent Pain Patients

NCT01841931
View directory record Official record
Conditions
Opioid Use Disorder, Opioid Dependence, Chronic Pain
Interventions
Buprenorphine/Naloxone
Drug
Lead sponsor
Theresa Jacob, PhD, MPH
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013
U.S. locations
1
States / cities
Brooklyn, New York
Source: ClinicalTrials.gov public record
Updated May 7, 2026 · Synced Sep 3, 2026, 9:45 AM EDT
Recruiting Phase 3 Interventional

A Study of Opevesostat (MK-5684) Versus Alternative Next-generation Hormonal Agent (NHA) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Post One NHA (MK-5684-004)

NCT06136650
View directory record Official record
Conditions
Metastatic Castration-resistant Prostate Cancer (mCRPC), Prostatic Neoplasms
Interventions
Opevesostat, Dexamethasone, Fludrocortisone acetate, Hydrocortisone, Abiraterone acetate, Prednisone acetate, Enzalutamide
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
1,314 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2030
U.S. locations
63
States / cities
Tucson, Arizona • Irvine, California • Los Angeles, California + 56 more
Source: ClinicalTrials.gov public record
Updated Aug 23, 2026 · Synced Sep 3, 2026, 9:45 AM EDT
Active, not recruiting No phase listed Observational

A Prospective Study Comparing VivAer to Alternative Surgical Procedures to Treat Nasal Airway Obstruction in Patients With Nasal Valve Dysfunction.

NCT06922955
View directory record Official record
Conditions
Nasal Airway Obstruction
Interventions
Not listed
Lead sponsor
Aerin Medical
Industry
Eligibility
22 Years to 85 Years
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
35
States / cities
Alexander City, Alabama • Birmingham, Alabama • Huntsville, Alabama + 27 more
Source: ClinicalTrials.gov public record
Updated Mar 22, 2026 · Synced Sep 3, 2026, 9:45 AM EDT
Completed Phase 2 Interventional

Alternate Day Buprenorphine Administration, Phase XII - 17

NCT00000235
View directory record Official record
Conditions
Opioid-Related Disorders
Interventions
Buprenorphine
Drug
Lead sponsor
National Institute on Drug Abuse (NIDA)
NIH
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Burlington, Vermont
Source: ClinicalTrials.gov public record
Updated Aug 16, 2005 · Synced Sep 3, 2026, 9:45 AM EDT
Completed Not applicable Interventional Results available

A Multisite Randomized Controlled Trial of Mindfulness Meditation Therapy for PTSD

NCT01532999
View directory record Official record
Conditions
Posttraumatic Stress Disorder
Interventions
Mindfulness Based Stress Reduction, Present Centered Group Therapy
Behavioral
Lead sponsor
US Department of Veterans Affairs
Federal
Eligibility
18 Years and older
Enrollment
254 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
3
States / cities
Tuscaloosa, Alabama • Decatur, Georgia • Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Apr 7, 2015 · Synced Sep 3, 2026, 9:45 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Title: Effect of Opioid Receptor Modulation on Alcohol Self-Administration and Neural Response to Alcohol Cues in Heavy Drinkers: Role of OPRM1 Gene Variation

NCT02639273
View directory record Official record
Conditions
AUD
Interventions
Nalmefene, Placebo
Drug · Other
Lead sponsor
National Institute on Alcohol Abuse and Alcoholism (NIAAA)
NIH
Eligibility
21 Years to 60 Years
Enrollment
13 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2023
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 30, 2026 · Synced Sep 3, 2026, 9:45 AM EDT
Recruiting Phase 1Phase 2 Interventional

Open-label Study of SKY-GJB2 in Pediatric Subjects With GJB2-mediated Hearing Loss

NCT07627971
View directory record Official record
Conditions
GJB2-mediated Hearing Loss, GJB2 Gene Mutation, DFNB1A
Interventions
SKY-GJB2
Combination Product
Lead sponsor
Skylark Bio Inc.
Industry
Eligibility
9 Months to 7 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
4
States / cities
Bethesda, Maryland • Boston, Massachusetts • Oklahoma City, Oklahoma + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 26, 2026 · Synced Sep 3, 2026, 9:45 AM EDT
Completed No phase listed Observational

Alternative Treatment Strategies for Stenotrophomonas Maltophilia Pneumonia

NCT06112938
View directory record Official record
Conditions
Stenotrophomonas Maltophilia Infection
Interventions
Antibiotic
Drug
Lead sponsor
Methodist Health System
Other
Eligibility
18 Years and older
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jul 27, 2025 · Synced Sep 3, 2026, 9:45 AM EDT
Recruiting Phase 2 Interventional

Alternate Doses and Dosing Schedules of Belantamab Mafodotin for Treatment of Triple-Class Refractory Multiple Myeloma

NCT05847569
View directory record Official record
Conditions
Recurrent Multiple Myeloma, Refractory Multiple Myeloma
Interventions
Belantamab Mafodotin, Biospecimen Collection, Bone Marrow Aspirate, Bone Marrow Biopsy, Computed Tomography, Magnetic Resonance Imaging, Positron Emission Tomography
Biological · Procedure
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2034
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Jul 13, 2026 · Synced Sep 3, 2026, 9:45 AM EDT
Active, not recruiting Phase 2 Interventional Results available

Ibrutinib + Venetoclax in Untreated WM

NCT04273139
View directory record Official record
Conditions
Waldenstrom Macroglobulinemia, MYD88 Gene Mutation
Interventions
IBRUTINIB, Venetoclax
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2028
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 10, 2026 · Synced Sep 3, 2026, 9:45 AM EDT
Approved For Marketing No phase listed Expanded access

An Expanded Access Program to Provide Nintedanib to Patients With Non-IPF ILD Who Have no Alternative Treatment Possibilities

NCT03843892
View directory record Official record
Conditions
Lung Diseases, Interstitial
Interventions
OFEV
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
Not listed
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
6
States / cities
Tucson, Arizona • Chesterfield, Missouri • Kalispell, Montana + 3 more
Source: ClinicalTrials.gov public record
Updated Dec 9, 2024 · Synced Sep 3, 2026, 9:45 AM EDT
No Longer Available No phase listed Expanded access

Expanded Access to Voxelotor for Patients With Sickle Cell Disease Who Have No Alternative Treatment Options

NCT03943615
View directory record Official record
Conditions
Sickle Cell Disease
Interventions
Voxelotor
Drug
Lead sponsor
Pfizer
Industry
Eligibility
12 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
18
States / cities
Birmingham, Alabama • Mobile, Alabama • Atlanta, Georgia + 15 more
Source: ClinicalTrials.gov public record
Updated Jul 17, 2023 · Synced Sep 3, 2026, 9:45 AM EDT